Evaluation of clinical and laboratory findings in patients diagnosed with COVID-19

Abstract

OBJECTIVE: Coronavirus disease 2019 (COVID-19) is an infectious disease that can lead to conditions ranging from mild upper respiratory tract infection to severe clinical manifestations, such as respiratory and multiorgan failure. Thus, this study was aimed at evaluating the clinical and laboratory findings of the patients followed up for COVID-19 in our hospital. PATIENTS AND METHODS: A total of 497 patients who were older than 18 years of age and had been diagnosed with COVID-19 were included in this study. Of the 497 patients diagnosed with COVID-19, 57.2% were male and 42.8% were female, and the mean age was 51.59±19.95 years. While the case-death rate was 9.2%, it was 36.8% in the intensive care unit. While lung involvement was detected in 72.2% of the patients, this rate was higher in the patients followed up in the ICU (98.8%). RESULTS: In the laboratory tests, the leukocytosis, lymphopenia, thrombocytopenia, C-reactive protein, alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, creatinine, creatine kinase, ferritin, procalcitonin, and D-dimer levels were higher in the deceased patients than in the surviving patients and were associated with mortality. The neutrophil/lymphocyte ratio was higher in the deceased patients when compared to the other patient groups, and it was also associated with increased mortality. Hypertension (8.6%) and diabetes mellitus (11.2%) were the most common underlying diseases in all of the patient groups. CONCLUSIONS: It was observed that the case-death rate was significantly higher in the ICU and mortality increased with advanced age. Moreover, comorbid factors were higher in patients who were followed up in the ICU and died. In the laboratory examinations, pathological findings were encountered at a higher rate, especially in the patients who died.

Keywords

• covid-19
• laboratory findings
• clinical findings
• mortality